The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Immune Checkpoint Inhibitors for Head and Neck Cancers
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, discusses immune checkpoint inhibitors for head and neck cancers.
Advertisement
Articles in this issue
about 12 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerabout 12 years ago
Sequencing Sorafenib and Lenvatinib in Thyroid Cancerabout 12 years ago
The Side Effects of Lenvatinibabout 12 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Related to this article
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5